The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 6, 2008, Pages 557-567

  Ciborowski, Michał ^a   Tomasiak, Marian ^a   Rusak, Tomasz ^a   Winnicka, Katarzyna ^a   Dobrzycki, Sławomir ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Aggregation; Porcine platelets; Secretion; Thromboelastography; Tirofiban

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBIN; THROMBOPLASTIN; TIROFIBAN; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; PLATELET PROCOAGULANT FACTOR; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOTTING; CALCIUM SIGNALING; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; IC 50; IN VITRO STUDY; LYSOSOME; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RELEASE REACTION; THROMBOELASTOGRAPHY; ANIMAL; CELL GRANULE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; SECRETION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESIVENESS;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CALCIUM SIGNALING; COLLAGEN; CYTOPLASMIC GRANULES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LYSOSOMES; MALE; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SUS SCROFA; THROMBELASTOGRAPHY; THROMBIN; TYROSINE;

EID: 58149109893     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283079e29     Document Type: Article

References (56)

1. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91:2645-2657.
2. Bennett JS. Platelet-fibrinogen interactions. Ann N Y Acad Sci 2001; 936:340-354.
3. Clark EA, Brugge JS. Integrins and signal transduction pathway. Science 1995; 268:233-239.
4. Patel D, Vaananen H, Jirouskova M, Hoffmann T, Bodian C, Coller BS. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood 2003; 101:929-936.
5. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 2004; 117:3415-3425.
6. Nurden AT, Nurden P. GPIIb/IIIa antagonists and other antiintegrins. Semin Vasc Med 2003; 3:123-130.
7. Cook JJ, Bednar B, Lynch JJ Jr, Gould RJ, Egbertson MS, Halczenko W, et al. Tirofiban (Aggrastat®). Cardiovasc Drug Rev 1999; 17:199-224.
8. Menozzi A, Merlini PA, Ardissino D. Tirofiban in acute coronary syndromes. Expert Rev Cardiovasc Ther 2005; 3:193-206.
9. Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothorac Surg 2005; 28:546-550.
10. Minoux H, Moitessier N, Chapleur Y, Maigret B. Elucidation of a common structure of selective fibrinogen receptor antagonists. J Comput Aided Mol Des 1998; 12:533-542.
11. The RESTORE Investigators. Randomized efficacy study of tirofiban for outcomes and restenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96:1445-1453.
12. PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet receptor inhibition in ischemic syndrome management. N Engl J Med 1998; 338:1498-1505.
13. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/ IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338:1488-1497.
14. Hughes GC, Post MJ, Simons M, Annex BH. Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. J Appl Physiol 2003; 94:1689-1701.
15. Hughes H. Swine in cardiovascular research. Lab Anim Sci 1986; 36:348-350.
16. Softeland E, Framstad T, Thorsen T, Holmsen H. Porcine platelets in vitro and in vivo studies: relevance to human thrombosis research. Eur J Haemtol 1992; 49:161-173.
17. Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168:178-195.
18. Tomasiak M, Stelmach H, Rusak T, Wysocka J. Nitric oxide and platelet energy metabolism. Acta Biochim Pol 2004; 51:789-803.
19. Holmsen H, Dangelmaier CA. Measurement of secretion of lysosomal acid glycosidases. Methods Enzymol 1989; 169:336-342.
20. Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A Colorimetric method for the measurement of platelet adhesion in microtiter plates. Biochemistry 1994; 216:444-450.
21. Brinkhous KM, Read MS. Fixation of platelets and platelet agglutination/ aggregation tests. Methods Enzymol 1989; 169:149-164.
22. + exchanger for the generation of procoagulant activity by porcine blood platelets. Platelets 2001; 12:436-442.
23. Rota S, Flynn PD, Wareham NJ, Baglin TP, Byrne CD. Is platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin? Thromb Res 1996; 83:329-338.
24. Marsh NA. Use of snake venom fractions in the coagulation laboratory. Blood Coagul Fibrinolysis 1998; 9:395-404.
25. +-ATPase in the development of platelet procoagulant response. Acta Biochim Pol 2007; 54:625-639.
26. Coller BS. (1992). Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings A, et al., editors. Heart and cardiovascular system. New York: Ravens Press Ltd. pp. 219-273.
27. Fuss C, Palmaz JC, Sprague EA. Fibrinogen: structure, function, and surface interactions. J Vasc Interv Radiol 2001; 12:677-682.
28. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69:58-178.
29. Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005; 25:1499-1505.
30. Thompson NT, Scrutton MC, Wallis RB. Particle volume changes associated with light transmittance changes in the platelet aggregometer: dependence upon aggregating agent and effectiveness of stimulus. Thromb Res 1986; 41:615-626.
31. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin KC, et al. Increased concentrations of tirofiban and their correlation with the inhibition of platelet aggregation with greater bolus doses of tirofiban.Am J Cardiol 2003; 91:334-336.
32. Danzi GB, Capuano C, Sesana M, Baglini R. Preliminary experience with the high bolus of tirofiban during percutaneous coronary intervention. Curr Med Res Opin 2003; 19:28-33.
33. Danzi GB, Capuano C, Sesana M, Baglini R. Safety of a high bolus of tirofiban in patients undergoing coronary stent placement. Catheter Cardiovasc Interv 2004; 61:179-184.
34. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Circulation 1998; 98:1616-1621.
35. Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Shimomura H, et al. Formation of platelet microaggregates correlates with adverse clinical outcome in patients with coronary artery disease. Thromb Haemost 2003; 89:681-686.
36. Dickfeld T, Ruf A, Pogatsa-Murray G, Muller I, Engelmann B, Taubitz W, et al. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists. Thromb Res 2001; 101:53-64.
37. Holmsen H (1981). Platelet secretion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Haemostasis and thrombosis: basic principles and clinical practice. Philadelphia: JB Lippincott Co. pp. 390-403.
38. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22:1381-1389.
39. Polasek J. Procoagulant potential of platelet a granules. Platelets 2004; 15:403-407.
40. Flaumenhaft R. Molecular basis of platelet granule secretion. Arterioscler Thromb Vasc Biol 2003; 23:1152-1160.
41. Roth GJ. A new 'kid' on the platelet thrombin receptor 'block': glycoprotein Ib-IX-V. Proc Natl Acad Sci U S A 2001; 98:1330-1331.
42. Burgoyne RD, Morgan A. Secretory granule exocytosis. Physiol Rev 2003; 83:581-632.
43. 3 regulates aIIb-mediated outside-in signaling. Blood 2005; 105:4345-4352.
44. 2 receptors to cause α-granule secretion by platelets. J Thromb Haemost 2003; 1:363-373.
45. 12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 2005; 105:3552-3560.
46. Woods VL, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb/IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261:15242-15251.
47. Nurden P, Poujol C, Durrieu-Jais C, Winckler J, Combrié R, Macchi L, et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood 1999; 93:1622-1633.
48. Nurden P. Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 1997; 78:1305-1315.
49. Suzuki H, Kaneko T, Sakamoto T, Nakagawa M, Miyamoto T, Yamada M, Tanoue K. Redistribution of a-granule membrane glycoprotein IIb/IIIa (integrin αIIbβ3) to the surface membrane of human platelets during the release reaction. J Electron Microsc 1994; 43:282-289.
50. Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. Thromb Haemost 2001; 86:266-275.
51. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89:1121-1132.
52. Wolfs JLN, Comfurius P, Rasmussen JT, Keuren JF, Lindhout T, Zwaal RF, Bevers EM. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62:1514-1525.
53. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin αIIbβ3 binds prothrombin and influence its activation. J Biol Chem 1997; 272:27183-27188.
54. Furman MI, Krueger LA, Frelinger AL 3rd, Barnard MR, Mascelli MA, Nakada MT, Michelson AD. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost 2000; 84:492-498.
55. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest 2005; 115:3355-3362.
56. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104:365-372.